9.1 IWGDF Risk Stratification Categories and Surveillance Intervals

Clinical Rationale and Evolution of IWGDF Risk Stratification

Diabetic foot ulceration is rarely an unpredictable or spontaneous event. Rather, it represents the cumulative endpoint of a recognizable triad: peripheral neuropathy, structural or biomechanical deformity, and unperceived repetitive mechanical trauma. Because the development of sensory loss, vascular insufficiency, and soft tissue breakdown progresses along an identifiable trajectory, preventative medicine relies on systematic risk stratification. The International Working Group on the Diabetic Foot (IWGDF) established a globally recognized, evidence-based risk classification system designed to categorize patients based on their specific risk of developing a primary or recurrent foot ulcer and to link each risk tier to a defined clinical surveillance frequency.

Historically, diabetic foot examinations were performed sporadically, often prompted only after a patient or caregiver observed drainage or systemic signs of sepsis. Implementing systematic risk stratification converts reactive wound treatment into proactive limb preservation. By identifying patients harboring pre-ulcerative lesions, subclinical ischemia, or sensory denervation, clinicians can introduce targeted offloading, customized footwear, aggressive hyperkeratosis debridement, and tailored education before the integumentary barrier is breached.

+-------------------------------------------------------------------------+
|          THE IWGDF RISK STRATIFICATION AND SURVEILLANCE CASCADE         |
+-------------------------------------------------------------------------+
| CATEGORY 0: Very Low Risk (No LOPS, No PAD)                             |
|             --> Annual Clinical Surveillance                            |
+-------------------------------------------------------------------------+
| CATEGORY 1: Low Risk (Isolated LOPS OR Isolated PAD, No Deformity)      |
|             --> Surveillance Every 6 to 12 Months                       |
+-------------------------------------------------------------------------+
| CATEGORY 2: Moderate Risk (LOPS + PAD, or LOPS/PAD + Deformity)         |
|             --> Surveillance Every 3 to 6 Months                        |
+-------------------------------------------------------------------------+
| CATEGORY 3: High Risk (LOPS/PAD + Prior DFU, Amputation, or ESRD)       |
|             --> Intensive Surveillance Every 1 to 3 Months              |
+-------------------------------------------------------------------------+

---

The Four IWGDF Risk Categories in Clinical Practice

The IWGDF risk classification categorizes patients into four distinct tiers numbered 0 through 3. Each category reflects a quantifiable escalation in annual ulcer risk and dictates a mandatory clinical reassessment interval.

Category 0: Very Low Risk

• Clinical Definition: A patient diagnosed with diabetes mellitus who demonstrates no Loss of Protective Sensation (LOPS) upon sensory testing and no Peripheral Artery Disease (PAD) upon objective vascular examination.
• Pathophysiology: Afferent somatic sensory feedback remains intact. The patient maintains the physiological protective pain threshold required to perceive focal shear stresses, ill-fitting footwear, foreign objects, and thermal extremes. Microvascular and macrovascular perfusion is sufficient to meet normal metabolic and tissue repair demands.
• Surveillance Frequency: Once annually.
• Preventative Interventions: Annual comprehensive sensory and vascular screening, reinforcement of general diabetes control, baseline patient education regarding appropriate commercial footwear, and instructions to report unexpected foot trauma immediately.

Category 1: Low Risk

• Clinical Definition: The presence of LOPS alone, OR the presence of PAD alone, in the absence of structural foot deformities.
• Pathophysiology:
  • LOPS Alone: Distal symmetric sensorimotor polyneuropathy has silenced the patient's protective sensory warning system. Repetitive low-pressure cycles during walking generate cumulative mechanical strain that goes unperceived. However, in the absence of osseous deformities, ground reaction forces remain relatively well-distributed across the plantar vault.
  • PAD Alone: Atherosclerotic occlusive disease or microvascular impairment diminishes baseline arterial inflow, compromising cellular oxygenation and nutritional delivery, but the patient retains protective sensation and will alter gait patterns or footwear when experiencing discomfort.
• Surveillance Frequency: Every 6 to 12 months.
• Preventative Interventions: Evaluation of shoe fit to prevent friction, consideration of commercial extra-depth footwear, assessment of independent self-care abilities, and noninvasive vascular testing if PAD is identified.

Category 2: Moderate Risk

• Clinical Definition: The presence of LOPS combined with PAD, OR the presence of LOPS combined with a structural foot deformity, OR the presence of PAD combined with a structural foot deformity.
• Pathophysiology: This category captures dangerous synergistic risk profiles. When LOPS coexists with a structural deformity (such as claw toes, hammer toes, hallux valgus, prominent metatarsal heads, or rigid flatfoot), focal vertical ground reaction forces and shear stresses are multiplied by several hundred percent over discrete skeletal prominences. Because the patient cannot feel this localized tissue trauma, repetitive ambulation rapidly initiates subcutaneous microvascular occlusion, tissue ischemia, autolysis, and subkeratotic hematoma formation. Similarly, when PAD coexists with LOPS or deformity, impaired tissue perfusion drastically diminishes the skin's tolerance to mechanical pressure, accelerating necrosis.
• Surveillance Frequency: Every 3 to 6 months.
• Preventative Interventions: Prescription therapeutic extra-depth shoes, custom-molded total-contact insoles, regular sharp debridement of pre-ulcerative hyperkeratosis (calluses), gait evaluation, and early vascular or surgical consultation if perfusion is critically low or deformities are unaccommodated.

Category 3: High Risk

• Clinical Definition: The presence of LOPS or PAD PLUS at least one of the following high-risk modifiers:
  1. History of a prior diabetic foot ulcer (DFU)
  2. History of a lower-extremity amputation (whether minor, such as a ray or toe resection, or major, such as transtibial or transfemoral)
  3. Presence of End-Stage Renal Disease (ESRD), particularly patients undergoing peritoneal dialysis or hemodialysis
• Pathophysiology: Patients in Category 3 have demonstrated biological vulnerability to dermal breakdown or have sustained profound anatomical and biomechanical alterations. A healed ulcer site consists of non-pliable scar tissue (predominantly Type I collagen lacking original elastic fibers) with markedly reduced tensile strength (rarely exceeding 70% to 80% of uninjured skin). Amputations permanently alter gait mechanics and load-bearing vectors, shifting extreme compensatory peak pressures to adjacent metatarsal heads or the contralateral extremity. ESRD exacerbates risk through chronic uremic calcification of arterial medias (Mönckeberg sclerosis), autonomic failure, altered tissue hydration, and hypervolemia-induced peripheral edema.
• Surveillance Frequency: Every 1 to 3 months.
• Preventative Interventions: Intensive podiatric care, prescription specialized or custom-molded therapeutic footwear with rigid rocker soles, home skin temperature monitoring, frequent callus debridement, nephrology and vascular coordination, and family caregiver engagement.

---

The Standardized Surveillance Examination Protocol

At every scheduled surveillance visit, the clinician must execute a structured, standardized clinical examination protocol consisting of five core assessments:

+-------------------------------------------------------------------------+
|             FIVE ESSENTIAL COMPONENTS OF FOOT SURVEILLANCE              |
+---+--------------------+------------------------------------------------+
| 1 | SENSORY ASSESSMENT | 10-g Semmes-Weinstein Monofilament + Vibration |
+---+--------------------+------------------------------------------------+
| 2 | VASCULAR EXAM      | Pedal pulses, CRT, dependent rubor, elevation  |
+---+--------------------+------------------------------------------------+
| 3 | DERMATOLOGIC CHECK | Calluses, fissures, maceration, tinea pedis    |
+---+--------------------+------------------------------------------------+
| 4 | MUSCULOSKELETAL    | Claw/hammer toes, Charcot collapse, equinus    |
+---+--------------------+------------------------------------------------+
| 5 | FOOTWEAR & ORTHOSES| Internal wear, foreign bodies, insole bottoming|
+---+--------------------+------------------------------------------------+

1. Neurological Assessment for Loss of Protective Sensation (LOPS)

• 10-g Semmes-Weinstein Monofilament (Size 5.07): The international gold standard for screening LOPS. When applied perpendicular to the skin until it buckles into a C-shape, it delivers exactly 10 grams of linear force. Testing must evaluate standardized plantar sites (minimally the plantar hallux, first metatarsal head, third metatarsal head, and fifth metatarsal head), avoiding calluses, scars, and open wounds. Use the chosen validated multi-site protocol with repeated applications and sham trials; classify LOPS from the protocol-defined pattern and a companion neurologic test rather than one uncertain response.
• Vibratory and Reflex Testing: Application of a 128-Hz tuning fork over the bony prominence of the dorsal hallux interphalangeal joint, biothesiometer vibration perception threshold (VPT > 25 V indicates high risk), and Achilles deep tendon reflex testing assess large myelinated A-alpha and A-beta nerve fiber function.

2. Vascular Examination for Peripheral Artery Disease (PAD)

• Palpation of Pedal Pulses: Bilateral palpation of the dorsalis pedis artery (on the dorsum of the foot between the first and second metatarsal bases) and the posterior tibial artery (posterior and inferior to the medial malleolus). Pulses are graded on a 0 to 4+ scale (0 = absent, 1+ = diminished, 2+ = normal, 3+ = bounding).
• Physical Signs of Ischemia: Evaluation for dependent rubor, pallor on limb elevation, prolonged capillary refill time (> 2 to 3 seconds), absence of digital hair growth, dystrophic thickened nails, and thin, shiny, cool atrophic skin. If pulses are diminished or absent, objective noninvasive vascular testing—including Ankle-Brachial Index (ABI) and absolute Toe Pressure / Toe-Brachial Index (TBI)—is mandatory.

3. Dermatologic Inspection for Pre-Ulcerative Pathology

• Complete visual inspection of the dorsal, plantar, medial, lateral, and interdigital surfaces under bright, direct illumination. The clinician must search actively for pre-ulcerative markers:
  • Hyperkeratotic Calluses: Rigid focal plaques that concentrate vertical ground reaction forces.
  • Subkeratotic Hemorrhage: Deep red, burgundy, or black discoloration beneath an intact callus, proving that dermal shearing and microvascular bleeding have already occurred.
  • Interdigital Maceration: White, soggy, softened skin between toes, frequently secondary to perspiration or untreated tinea pedis, which creates open portals for ascending bacterial cellulitis.
  • Heel Fissures: Deep cutaneous cracks through dry, anhidrotic skin that extend into the vascularized dermis.

4. Musculoskeletal and Biomechanical Examination

• Identification of structural deformities that create abnormal focal pressure concentrations:
  • Claw Toes and Hammer Toes: Extensor-flexor imbalance causing MTP joint hyperextension and PIP/DIP flexion, creating high dorsal pressures against the shoe toe box and distal subluxation of the protective plantar fat pad away from the metatarsal heads.
  • Hallux Valgus (Bunions): Medial deviation of the first metatarsal head and lateral deviation of the great toe, leading to prominent medial osseous friction.
  • Prominent Metatarsal Heads: Plantarflexed metatarsals that focalize ground impact.
  • Charcot Foot Deformity: Tarsometatarsal or midtarsal collapse producing a rigid "rocker-bottom" foot with profound midplantar osseous protrusions.
  • Ankle Equinus: Inability to dorsiflex the talocrural joint beyond neutral (0°) with the knee extended, dramatically increasing forefoot ground impact during terminal stance.

5. Footwear and Orthotic Surveillance

• A comprehensive diabetic foot examination is incomplete without evaluating the patient's shoes and orthoses. The clinician must inspect:
  • Shoes for appropriate length (leaving 1/2 inch clearance beyond the longest toe) and width (matching the ball of the foot without compression).
  • The interior lining for torn seams, protruding stitching, or embedded foreign objects (e.g., small stones, needles, thumbtacks).
  • Outsoles for asymmetric or extreme wear patterns reflecting biomechanical abnormalities.
  • Custom insoles for permanent compression ("bottoming out") of cushioning layers such as Plastazote, which eliminates pressure-relieving efficacy.

---

Summary of IWGDF Categories and Surveillance Protocol

---